BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26625525)

  • 1. [Effect of Antihypertensive Drugs on Regression of Left Ventricular Hypertrophy].
    Koziolova NA; Shatunova IM
    Kardiologiia; 2015; 55(6):88-97. PubMed ID: 26625525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of the effect of antihypertensive drugs on left ventricular hypertrophy regression].
    Koziolova NA; Shatunova IM
    Kardiologiia; 2014; 54(3):82-91. PubMed ID: 25102754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in left ventricular geometry during antihypertensive treatment.
    Salvetti M; Paini A; Bertacchini F; Stassaldi D; Aggiusti C; Agabiti Rosei C; Bassetti D; Agabiti-Rosei E; Muiesan ML
    Pharmacol Res; 2018 Aug; 134():193-199. PubMed ID: 29959031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication.
    Yoshida C; Goda A; Naito Y; Nakaboh A; Matsumoto M; Otsuka M; Ohyanagi M; Hirotani S; Lee-Kawabata M; Tsujino T; Masuyama T
    J Hypertens; 2011 Feb; 29(2):357-63. PubMed ID: 21052021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system.
    du Cailar G; Fesler P; Ribstein J; Mimran A
    Hypertension; 2010 Nov; 56(5):865-70. PubMed ID: 20921428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antihypertensive treatment and left ventricular hypertrophy].
    Agabiti-Rosei E; Muiesan ML; Rizzoni D
    Ann Ital Med Int; 1993 Oct; 8 Suppl():97S-103S. PubMed ID: 8117529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of changes in blood pressure and left ventricular mass induced by antihypertensive treatment on ventricular arrhythmias in essential hypertension.
    Muiesan ML; Zulli R; Rizzoni D; Calebich S; Malerba M; Porteri E; Agabiti-Rosei E
    J Hypertens Suppl; 1993 Dec; 11(5):S104-5. PubMed ID: 8158296
    [No Abstract]   [Full Text] [Related]  

  • 10. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy.
    Kucukler N; Kurt IH; Topaloglu C; Gurbuz S; Yalcin F
    J Cardiovasc Med (Hagerstown); 2012 Mar; 13(3):181-6. PubMed ID: 22306782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy.
    Kjeldsen SE; Strand A; Julius S; Okin PM
    J Clin Hypertens (Greenwich); 2006 Jul; 8(7):487-92. PubMed ID: 16849902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of therapeutic studies on regression of left ventricular hypertrophy.
    Schmieder RE; Schlaich MP
    Adv Exp Med Biol; 1997; 432():191-8. PubMed ID: 9433526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of left ventricular hypertrophy is a key goal of hypertension management.
    Zhang R; Crump J; Reisin E
    Curr Hypertens Rep; 2003 Aug; 5(4):301-8. PubMed ID: 12844464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of left ventricular hypertrophy in hypertensive patients.
    Tamargo J; Delpón E; Valenzuela C
    Eur Heart J; 1993 Nov; 14 Suppl J():102-6. PubMed ID: 8281952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996).
    Schmieder RE; Schlaich MP; Klingbeil AU; Martus P
    Nephrol Dial Transplant; 1998 Mar; 13(3):564-9. PubMed ID: 9550628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).
    Sezai A; Osaka S; Yaoita H; Arimoto M; Hata H; Shiono M; Sakino H
    Ann Thorac Cardiovasc Surg; 2016 Jun; 22(3):161-7. PubMed ID: 27086671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
    Solomon SD; Appelbaum E; Manning WJ; Verma A; Berglund T; Lukashevich V; Cherif Papst C; Smith BA; Dahlöf B;
    Circulation; 2009 Feb; 119(4):530-7. PubMed ID: 19153265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of diastolic dysfunction in hypertensive left ventricular hypertrophy.
    Bella JN
    Am J Hypertens; 2006 Sep; 19(9):937-8. PubMed ID: 16942936
    [No Abstract]   [Full Text] [Related]  

  • 20. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies.
    Schmieder RE; Martus P; Klingbeil A
    JAMA; 1996 May; 275(19):1507-13. PubMed ID: 8622227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.